Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
DB53RG
|
|||
Drug Name |
BMS-986278
|
|||
Synonyms |
BMS-986278; 4UN9AOU6G8; 2170126-74-4; UNII-4UN9AOU6G8; (1S,3S)-3-((2-Methyl-6-(1-methyl-5-(((methyl(propyl)carbamoyl)oxy)methyl)-1H-1,2,3-triazol-4-yl)pyridin-3-yl)oxy)cyclohexane-1-carboxylic acid; Cyclohexanecarboxylic acid, 3-((2-methyl-6-(1-methyl-5-((((methylpropylamino)carbonyl)oxy)methyl)-1H-1,2,3-triazol-4-yl)-3-pyridinyl)oxy)-, (1S,3S)-; Cyclohexanecarboxylic acid, 3-[[2-methyl-6-[1-methyl-5-[[[(methylpropylamino)carbonyl]oxy]methyl]-1H-1,2,3-triazol-4-yl]-3-pyridinyl]oxy]-, (1S,3S)-; CHEMBL5087506; SCHEMBL19715798; GTPL11798; EX-A5516; BDBM50581552; BMS986278; AKOS040757379; compound 33 [PMID: 34709814]; MS-28028; CS-0256104; F83338; (1S,3S)-3-[2-methyl-6-[1-methyl-5-[[methyl(propyl)carbamoyl]oxymethyl]triazol-4-yl]pyridin-3-yl]oxycyclohexane-1-carboxylic acid
Click to Show/Hide
|
|||
Drug Type |
Small molecule
|
|||
Indication | Pulmonary fibrosis [ICD-11: CB03.4; ICD-10: J84.1] | Phase 2 | [1] | |
Company |
Bristol-Myers Squibb
|
|||
Structure |
Download2D MOL |
|||
Formula |
C22H31N5O5
|
|||
Canonical SMILES |
CCCN(C)C(=O)OCC1=C(N=NN1C)C2=NC(=C(C=C2)OC3CCCC(C3)C(=O)O)C
|
|||
InChI |
InChI=1S/C22H31N5O5/c1-5-11-26(3)22(30)31-13-18-20(24-25-27(18)4)17-9-10-19(14(2)23-17)32-16-8-6-7-15(12-16)21(28)29/h9-10,15-16H,5-8,11-13H2,1-4H3,(H,28,29)/t15-,16-/m0/s1
|
|||
InChIKey |
UEUNDURNLYLSNB-HOTGVXAUSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Lysophosphatidic acid receptor 1 (LPAR1) | Target Info | Antagonist | [2] |
KEGG Pathway | Rap1 signaling pathway | |||
Neuroactive ligand-receptor interaction | ||||
PI3K-Akt signaling pathway | ||||
Gap junction | ||||
Pathways in cancer | ||||
NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
Pathway Interaction Database | LPA receptor mediated events | |||
Reactome | G alpha (q) signalling events | |||
G alpha (i) signalling events | ||||
Lysosphingolipid and LPA receptors | ||||
WikiPathways | Myometrial Relaxation and Contraction Pathways | |||
Gastrin-CREB signalling pathway via PKC and MAPK | ||||
Small Ligand GPCRs | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT04308681) A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants With Pulmonary Fibrosis. U.S.National Institutes of Health. | |||
REF 2 | Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA(1)) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD). BMJ Open Respir Res. 2021 Dec;8(1):e001026. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.